RxDoctor Payments Data

Motasem Afyouni, MD

Internal Medicine · Mishawaka, INNPI 1306011606

Payments from drug & device makers

$902in general payments, 2019–2025

Across 61 payments — averaging $14.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$164
  • Pfizer$142
  • AstraZeneca$124
  • Novo Nordisk$98
  • AbbVie$42
  • Neurocrine Biosciences, Inc.$41
  • plus $291 from 12 others

What the payments were for

  • Food & beverage$902100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$902 in reported general payments places this provider in the 70th percentile of 1,747 internal medicine providers in Indiana.

See all internal medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$216,014
Medicare patients
742
Services billed
2,722

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban93$105,220
XareltoRivaroxaban27$35,563
OzempicSemaglutide22$33,532
MounjaroTirzepatide21$30,786
JanuviaSitagliptin Phosphate19$27,097
Breztri AerosphereBudesonide/Glycopyr/Formoterol21$13,590
Lantus SolostarInsulin Glargine,hum.Rec.Anlog24$5,693
Humalog Kwikpen U-100Insulin Lispro13$2,790
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$2,265
Albuterol Sulfate HfaAlbuterol Sulfate65$2,220
Gabapentin128$2,191
SynthroidLevothyroxine Sodium28$2,069
Bupropion XlBupropion Hcl64$1,867
Atorvastatin Calcium317$1,865
Diltiazem 12hr ErDiltiazem Hcl14$1,614

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$142$105,22093 claims
Johnson & JohnsonXarelto$11$35,56327 claims
Novo NordiskOzempic$98$33,53222 claims
Lilly USA, LLCMounjaro$28$30,78621 claims
AstraZenecaBreztri Aerosphere$124$13,59021 claims
AbbVieSynthroid$42$2,06928 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,747 internal medicine providers in Indiana.

Other internal medicine in Mishawaka

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →